Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer

Enzalutamide (ENZA) is a frequently used therapy in metastatic castration‐resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Csizmarik, Anita, Keresztes, Dávid, Nagy, Nikolett, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Tornyi, Ilona, Lázár, József, Takács, László, Kramer, Gero, Sevcenco, Sabina, Maj‐Hes, Agnieszka, Jurányi, Zsolt, Hadaschik, Boris, Nyirády, Péter, Szarvas, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539937/
https://www.ncbi.nlm.nih.gov/pubmed/35689436
http://dx.doi.org/10.1002/ijc.34159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539937/
https://www.ncbi.nlm.nih.gov/pubmed/35689436
http://dx.doi.org/10.1002/ijc.34159

Ejemplares similares